Abstract
In patients with rheumatoid arthritis who do not respond to therapy with salicylates or nonsteroidal anti-inflammatory agents, stronger and potentially more toxic drugs are then considered. At the present time in the United States, this generally means a trial of hydroxychloroquine, gold, penicillamine, azathioprine, or cyclophosphamide. Each of these drugs is discussed with regard to pharmacology and possible modes of action, pertinent clinical studies, and toxicity.
MeSH terms
-
Arthritis, Rheumatoid / drug therapy*
-
Aurothioglucose / therapeutic use
-
Azathioprine / adverse effects
-
Azathioprine / pharmacology
-
Azathioprine / therapeutic use
-
Chloroquine / adverse effects
-
Chloroquine / therapeutic use
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / pharmacology
-
Cyclophosphamide / therapeutic use
-
Gold / adverse effects
-
Gold Sodium Thiomalate / therapeutic use
-
Humans
-
Hydroxychloroquine / therapeutic use
-
Penicillamine / adverse effects
-
Penicillamine / pharmacology
-
Penicillamine / therapeutic use
-
Retinal Diseases / chemically induced
Substances
-
Gold Sodium Thiomalate
-
Aurothioglucose
-
Hydroxychloroquine
-
Gold
-
Chloroquine
-
Cyclophosphamide
-
Penicillamine
-
Azathioprine